GlassScriptPhysician profile
Ashley M Rogier
NPI 1568013845
$2,647.84
in general payments reported to CMS, 2019-2025
30 companies · $544 in 2025
The $544 reported for 2025 was more than what 76% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $371 · 2022: $331 · 2023: $706 · 2024: $696 · 2025: $544.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,946.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,945.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $397.77 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $268.97 | 2021-2025 | |
| Glaxosmithkline, LLC. | $251.03 | 2023-2025 | Shingrix, Trelegy Ellipta, Arexvy |
| Abbvie INC. | $243.74 | 2021-2024 | |
| Astrazeneca Pharmaceuticals LP | $204.41 | 2022-2025 | Farxiga, Airsupra |
| Lilly USA, LLC | $163.16 | 2021-2025 | Zepbound, Mounjaro, Jardiance |
| Otsuka America Pharmaceutical, INC. | $153.04 | 2022-2025 | Rexulti |
| Exact Sciences Corporation | $106.16 | 2023-2025 | Cologuard Collection Kit |
| Amarin Pharma, INC. | $86.98 | 2021 | |
| Lundbeck LLC | $73.28 | 2024-2025 | Rexulti |
| Astellas Pharma US INC | $71.64 | 2023-2024 | Veozah, Myrbetriq |
| Janssen Pharmaceuticals, INC | $65.06 | 2021-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $61.86 | 2022-2025 | Xifaxan |
| Supernus Pharmaceuticals, INC. | $55.16 | 2021-2022 | |
| Abbott Laboratories | $54.24 | 2023-2024 | Freestyle Libre 3 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $48.55 | 2025 | |
| Axsome Therapeutics, INC. | $47.35 | 2024-2025 | Auvelity, Symbravo |
| Amgen INC. | $45.92 | 2022-2024 | Evenity, Prolia |
| Dexcom, INC. | $43.33 | 2022-2025 | Dexcom G6 Transmitter |
| Merck Sharp & Dohme LLC | $29.06 | 2021 | |
| Dynavax Technologies Corporation | $22.94 | 2023 | Heplisav-B |
| Biohaven Pharmaceutical Holding Company LTD. | $22.35 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $20.86 | 2021 | |
| Sumitomo Pharma America, INC. | $19.47 | 2025 | Gemtesa |
| Phadia US INC. | $18.52 | 2023 | Immunocap |
| Esperion Therapeutics, INC. | $17.55 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $15.04 | 2021 | |
| Philips North America LLC | $15.00 | 2023 | |
| Corium, LLC | $13.46 | 2023 | Azstarys |
| Almatica Pharma LLC | $11.94 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ashley Rogier listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.